Global Pharmaceutical Glass Tubular Vial and Ampoule Market Size By Type (Vial, Ampoule), By Application (Pharmaceutical Company, Hospital Research Room), By Region, And Segment Forecasts, 2023 to 203...

The Global Pharmaceutical Glass Tubular Vial and Ampoule Market was valued at USD 9.1 billion in 2023 and is projected to reach USD 15.6 billion by 2031, expanding at a CAGR of 6.7% during the forecast period of 2023–2031. This market is primarily driven by the increasing demand for safe and reliable drug packaging solutions, growing pharmaceutical production, and rising global vaccination and injectable drug administration rates. Glass tubular vials and ampoules offer high chemical resistance, durability, and integrity, making them essential in ensuring the safety and efficacy of pharmaceutical products.

Drivers

1. Growth in Injectable Drug Consumption:

Injectable drugs are gaining preference due to their rapid therapeutic effect, especially for chronic illnesses, vaccines, and biologics. The demand for glass vials and ampoules has surged in line with the rise in vaccine programs and biologic drug formulations.

2. Increasing Pharmaceutical Manufacturing:

Pharmaceutical manufacturers are ramping up production capacities to meet the growing global demand, especially in emerging markets. This has led to increased procurement of tubular glass containers, which are the primary packaging choice due to their inertness and compatibility with sensitive drug formulations.

3. Advancements in Manufacturing Technologies:

Automation in the forming and inspection of glass vials and ampoules is improving quality, throughput, and reducing defect rates. These advancements ensure compliance with strict regulatory standards.

Restraints

1. Fragility of Glass and Risk of Breakage:

Despite their advantages, glass containers are fragile and susceptible to breakage during handling and transport, which can lead to drug contamination and loss.

2. Availability of Alternative Packaging Materials:

The emergence of high-performance polymer containers with improved break resistance and similar barrier properties poses a competitive threat to traditional glass formats.

Opportunity

1. Rising Demand from Biopharmaceutical Sector:

The rise in biologics and personalized medicine is creating lucrative opportunities for glass vial and ampoule manufacturers, as these drugs require premium packaging with superior protection and stability.

2. Expansion in Emerging Markets:

Regions such as Asia-Pacific and Latin America are witnessing rapid growth in healthcare infrastructure, pharmaceutical production, and regulatory reforms, offering attractive expansion prospects for packaging solution providers.

Market by System Type Insights

Based on system type, the Tubular Glass Vials segment accounted for the largest market share in 2023, owing to their extensive use in storing vaccines, biologics, and injectable medicines. These vials offer excellent dimensional consistency and compatibility with automatic filling lines. Meanwhile, the Tubular Glass Ampoules segment is also gaining momentum due to its single-dose packaging advantage, especially in emergency and sterile applications.

Market by End-use Insights

The Pharmaceutical Manufacturing segment dominated the market in 2023, holding over 50% of the global share. This is attributed to the widespread use of tubular vials and ampoules in commercial drug production. The Contract Manufacturing Organizations (CMOs) segment is expected to witness the fastest growth, driven by the outsourcing trend among pharmaceutical companies seeking scalable, flexible packaging solutions.

Market by Regional Insights

Asia-Pacific emerged as the leading regional market in 2023, fueled by robust pharmaceutical manufacturing activities in countries like China and India, favorable government policies, and cost advantages. North America and Europe follow closely due to advanced healthcare systems and the presence of major biopharma companies. Latin America and the Middle East & Africa are expected to experience steady growth, supported by improving healthcare infrastructure and expanding drug access programs.

Competitive Scenario

Key players in the Global Pharmaceutical Glass Tubular Vial and Ampoule Market include:

Schott AG, Gerresheimer AG, Nipro Corporation, DWK Life Sciences, SGD Pharma, Stevanato Group, Shandong Medicinal Glass Co., Ltd., and Arab Pharmaceutical Glass Co. These companies are investing in capacity expansion, technological upgrades, and strategic collaborations to cater to evolving pharmaceutical packaging needs.

Scope of Work – Global Pharmaceutical Glass Tubular Vial and Ampoule Market

Report Metric Details

Market Size (2023) USD 9.1 billion

Projected Market Size (2031) USD 15.6 billion

CAGR (2023–2031) 6.7%

Market Segments By System Type (Tubular Vials, Tubular Ampoules); By End-use (Pharmaceutical Manufacturing, CMOs, Others); By Region

Growth Drivers Rising injectable drug demand, Biologics expansion, Technological advancements in glass forming

Opportunities Growth in biopharmaceuticals, Emerging market expansion

Key Market Developments

2023: Stevanato Group launched a next-gen sterile tubular vial solution compatible with high-speed filling lines, enhancing pharmaceutical production efficiency.

2024: Schott AG expanded its manufacturing facility in India to meet growing regional demand for high-quality pharmaceutical glass packaging.

2025: Gerresheimer AG introduced an eco-friendly tubular glass vial series with reduced carbon footprint and enhanced recycling potential.

FAQs

1. What is the current market size of the Global Pharmaceutical Glass Tubular Vial and Ampoule Market?

The market was valued at USD 9.1 billion in 2023.

2. What is the major growth driver of the Global Pharmaceutical Glass Tubular Vial and Ampoule Market?

The major growth driver is the rising demand for injectable drugs and vaccines.

3. Which is the largest region during the forecast period in the Global Pharmaceutical Glass Tubular Vial and Ampoule Market?

Asia-Pacific is the largest region due to its strong pharmaceutical production base an